Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC FOLFIRI versus fruquintinib for previously treated colorectal cancer liver metastasis
ChiCTR2400093889Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, levoleucovorin, fluorouracil, bevacizumab and fruquintinib in colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
irinotecanlevoleucovorinfluorouracilbevacizumabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400093889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093889.